BGIM
HZNP

Brandywine Global Investment Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Brandywine Global Investment Management’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-218,649
Closed -$23.9M – 779
2023
Q1 		$23.9M Sell
218,649
-310,344
-59% -$34.3M 0.19% 132
2022
Q4 		$60.2M Sell
528,993
-144,930
-22% -$12M 0.47% 57
2022
Q3 		$41.7M Buy
+673,923
New +$47.1M 0.39% 74
2020
Q3 		– Sell
-79
Closed -$5K – 793
2020
Q2 		$5K Sell
79
-37,146
-100% -$1.59M ﹤0.01% 717
2020
Q1 		$1.1M Sell
37,225
-927,602
-96% -$31.4M 0.01% 510
2019
Q4 		$34.9M Sell
964,827
-119,125
-11% -$3.65M 0.25% 96
2019
Q3 		$29.5M Buy
1,083,952
+973,669
+883% +$25.2M 0.22% 104
2019
Q2 		$2.65M Sell
110,283
-1,063,265
-91% -$27M 0.02% 507
2019
Q1 		$31M Sell
1,173,548
-313,599
-21% -$7.43M 0.21% 100
2018
Q4 		$29.1M Sell
1,487,147
-991,051
-40% -$19.4M 0.22% 107
2018
Q3 		$48.5M Sell
2,478,198
-444,512
-15% -$8.45M 0.3% 81
2018
Q2 		$48.4M Sell
2,922,710
-824,097
-22% -$12.6M 0.31% 85
2018
Q1 		$53.2M Sell
3,746,807
-413,667
-10% -$6.11M 0.34% 75
2017
Q4 		$60.7M Buy
4,160,474
+149,854
+4% +$2.1M 0.36% 70
2017
Q3 		$50.9M Buy
4,010,620
+51,818
+1% +$659K 0.32% 74
2017
Q2 		$47M Buy
3,958,802
+428,546
+12% +$5.33M 0.3% 79
2017
Q1 		$52.2M Buy
3,530,256
+1,038,483
+42% +$16.8M 0.33% 72
2016
Q4 		$40.3M Sell
2,491,773
-152,985
-6% -$2.77M 0.26% 90
2016
Q3 		$48M Sell
2,644,758
-164,624
-6% -$3.22M 0.32% 82
2016
Q2 		$46.3M Buy
2,809,382
+340,618
+14% +$5.51M 0.31% 82
2016
Q1 		$40.9M Buy
2,468,764
+198,244
+9% +$3.47M 0.27% 87
2015
Q4 		$49.2M Buy
+2,270,520
New +$44.2M 0.31% 80

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Brandywine Global Investment Management's HZNP Position: Q2 2023 in Review

Brandywine Global Investment Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2023, closing a stake of 218,649 shares — an estimated $23.9M sold.

Brandywine Global Investment Management first reported a position in HZNP in Q4 2015 and held it in 22 quarters. The position peaked at $60.7M in Q4 2017. 517 funds tracked by Wall St. Rank hold HZNP as of Q2 2023.

  • Brandywine Global Investment Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2023 after selling out during the quarter.
  • Brandywine Global Investment Management sold 218,649 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2023, an estimated $23.9M.
  • Brandywine Global Investment Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 22 quarters.
  • Brandywine Global Investment Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $60.7M in Q4 2017.
  • 517 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2023.

Based on Brandywine Global Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.